All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Precision immuno-oncology approach for four malignant tumors in siblings with constitutional mismatch repair deficiency syndrome

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F65269705%3A_____%2F24%3A00079928" target="_blank" >RIV/65269705:_____/24:00079928 - isvavai.cz</a>

  • Alternative codes found

    RIV/00216224:14110/24:00136210

  • Result on the web

    <a href="https://www.nature.com/articles/s41698-024-00597-8" target="_blank" >https://www.nature.com/articles/s41698-024-00597-8</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.1038/s41698-024-00597-8" target="_blank" >10.1038/s41698-024-00597-8</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    Precision immuno-oncology approach for four malignant tumors in siblings with constitutional mismatch repair deficiency syndrome

  • Original language description

    Constitutional mismatch repair deficiency (CMMRD) is a rare syndrome characterized by an increased incidence of cancer. It is caused by biallelic germline mutations in one of the four mismatch repair genes (MMR) genes: MLH1, MSH2, MSH6, or PMS2. Accurate diagnosis accompanied by a proper molecular genetic examination plays a crucial role in cancer management and also has implications for other family members. In this report, we share the impact of the diagnosis and challenges during the clinical management of two brothers with CMMRD from a non-consanguineous family harbouring compound heterozygous variants in the PMS2 gene. Both brothers presented with different phenotypic manifestations and cancer spectrum. Treatment involving immune checkpoint inhibitors significantly contributed to prolonged survival in both patients affected by lethal gliomas. The uniform hypermutation also allowed immune-directed treatment using nivolumab for the B-cell lymphoma, thereby limiting the intensive chemotherapy exposure in this young patient who remains at risk for subsequent malignancies.

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database

  • CEP classification

  • OECD FORD branch

    30204 - Oncology

Result continuities

  • Project

    Result was created during the realization of more than one project. More information in the Projects tab.

  • Continuities

    P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Others

  • Publication year

    2024

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    npj Precision Oncology

  • ISSN

    2397-768X

  • e-ISSN

    2397-768X

  • Volume of the periodical

    8

  • Issue of the periodical within the volume

    1

  • Country of publishing house

    DE - GERMANY

  • Number of pages

    9

  • Pages from-to

    110

  • UT code for WoS article

    001228647800002

  • EID of the result in the Scopus database

    2-s2.0-85193939549